Certara's software arm grows 11% in third quarter while services shrink
The drug-development modelling provider posted 4% quarterly revenue growth, trimmed its net loss and tightened its full-year growth forecast, while appointing a new product chief.
Certara's software business is now carrying the group. Software sales rose 11% to $48.8M in the third quarter, while services revenue slipped 2%, according to results the Nasdaq-listed company published on 5 November.
Total revenue from continuing operations reached $94.9M, a 4% increase. On those figures, software accounts for about half of the quarter's sales. Certara supplies modelling software and related services used in drug development.
The company reported a net loss of $3.6M, smaller than before, and closed the period with $214.9M in cash. The information available does not include the prior-year loss or other balance-sheet lines, so the scale of the improvement cannot be measured here.
For 2026 as a whole, Certara now expects revenue growth of 2% to 3%, a tighter range than it had previously signalled. It also said Grant Peterson became Chief Product Officer on 2 November. No details were given on his remit or on any change to the product roadmap.
Why it matters
- Software, not services, is generating Certara's growth, which matters to sponsors choosing between licensing modelling tools and buying outsourced modelling work.
- A full-year growth outlook of 2% to 3% points to modest expansion for the group overall.
- The new Chief Product Officer's priorities have not been disclosed, so any shift in product strategy remains unclear.
Company's press release (SEC filing): Certara, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
